Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Advanced Cancer Therapeutics

Request full access

Advanced Cancer Therapeutics, LLC engages in the discovery, development, manufacture, and commercialization of cancer therapeutics

Louisville, United StatesFounded 2007Biotech & Life Sciences

About Advanced Cancer Therapeutics

Advanced Cancer Therapeutics (ACT) is a privately held biotechnology company established in January 2007, operating out of Louisville, Kentucky. The firm was created to commercialize pioneering cancer research emerging from the University of Louisville's James Graham Brown Cancer Center. ACT operates on a distinctive business model built upon a strategic partnership with the Brown Cancer Center and the University of Louisville Research Foundation. This arrangement grants ACT exclusive worldwide licenses to novel cancer therapeutics discovered at the center under pre-negotiated terms, enabling the company to rapidly advance these discoveries toward pharmaceutical partnerships and eventual patient use.

The company was founded by key figures from the University of Louisville, including Dr. Donald M. Miller, a distinguished physician-scientist who served as Director of the Brown Cancer Center. Dr. Miller's extensive research background is in gene-targeted therapeutics and the development of oligonucleotide-based therapies, such as the DNA aptamer AS1411, which was the first of its kind to be tested in cancer patients. This scientific foundation is central to the company's mission. The initial leadership team included Randall B. Riggs, who was appointed President and CEO in January 2008. Riggs brought extensive corporate strategy and business development experience from his prior roles at pharmaceutical and biotech companies like Eli Lilly & Company, Lexicon Pharmaceuticals, and BioCryst Pharmaceuticals.

ACT’s primary business is the identification, licensing, and early-stage development of promising anti-cancer drug candidates. Its revenue model is centered on advancing these assets through preclinical and early clinical stages to a point where they can be partnered or out-licensed to larger pharmaceutical companies for late-stage development, commercialization, and manufacturing. A significant milestone for the company was advancing its first-in-class drug candidate, PFK-158, into Phase 1 human clinical trials. PFK-158 is a small molecule inhibitor of PFKFB3, a novel cancer metabolism target crucial for tumor growth. By inhibiting this target, the drug aims to prevent tumor cells in cancers like melanoma, lung, colon, and breast from using glucose as a fuel source. The company has also developed preclinical programs targeting Choline Kinase (CK), another enzyme over-expressed in many solid tumors.

Source: Dealroom company data

At a glance

Status
Closed
Employees
1
Open positions
None listed
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
GRANTOther financing Oct 2012 $158K — National Cancer Institute (NCI) ↗
SERIES A✓Equity / VC Jul 2010 $10M $40M Undisclosed —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Advanced Cancer Therapeutics website traffic

Latest recorded traffic for Advanced Cancer Therapeutics is 290 monthly website visits, down 14.7% over the last three months. Advanced Cancer Therapeutics's team grew 0% over the past year.

Latest monthly visits290 3-month web change-14.7% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Advanced Cancer Therapeutics in the Louisville ecosystem

Live from Dealroom

The Advanced Cancer Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • Commonwealth Capital Ventures
  • National Cancer Institute (NCI)

Other known investors1 additional known investor

  • University of Louisville
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Louisville HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Advanced Cancer Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Advanced Cancer Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.